Last reviewed · How we verify
NCT03827876
Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis
Phase 4 trial testing Enstilar 0.005%-0.064% Topical Foam in Psoriasis in 30 participants. Currently enrolling.
15 September 2019
Quick facts
| Lead sponsor | Psoriasis Treatment Center of Central New Jersey |
|---|---|
| Phase | Phase 4 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 16 January 2019 |
| Primary completion | 15 September 2019 |
| Estimated completion | 15 December 2019 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Enstilar 0.005%-0.064% Topical Foam — full drug profile →
Conditions studied
- Psoriasis — all drugs for Psoriasis →
Sponsor
Psoriasis Treatment Center of Central New Jersey — full company profile →
Who can join
18 and older, any sex, with Psoriasis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
4 weeks of adjunctive therapy of Enstilar® QD followed by 12 weeks QOD to patients with 2-10% BSA who are receiving etanercept or adalimumab for at least 24 weeks
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03827876
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Enstilar 0.005%-0.064% Topical Foam
Trials testing the same drug.
- NCT03080545 — Enstilar in Combination With Biologic Agents · Phase 4 · completed
Other recruiting trials for Psoriasis
Currently open trials in the same condition.
- NCT07471048 — A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects With Psoria · NA · recruiting
- NCT07449234 — A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis · recruiting
- NCT07234838 — Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO) · recruiting
- NCT07194200 — Safety and Efficacy of Lactobacillus Plantarum for Psoriasis: A Randomized Double-Blind Placebo-Controlled Trial · Phase 2 · recruiting
- NCT07250997 — PALLAS Laser for Skin Diseases · NA · recruiting
Other Psoriasis Treatment Center of Central New Jersey trials
Trials by the same sponsor.
- NCT06773455 — Tralokinumab for Dupilumab Failures · Phase 4 · active not recruiting
- NCT06103695 — Vtama in Psoriasis Patients Being Treated With Biologics. · Phase 4 · completed
- NCT06329258 — Combination of Sotyktu and Enstilar for Plaque Psoriasis · Phase 4 · completed
- NCT05285839 — Dupixent and Narrowband UVB for Atopic Dermatitis · Phase 4 · recruiting
- NCT04372277 — Taltz in Combination With Enstilar for Psoriasis · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03827876 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Psoriasis Treatment Center of Central New Jersey
- Last refreshed: 4 February 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03827876.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing